US need for clarity set to delay MRA (mutual recognition agreement)
This article was originally published in Clinica
The starting date of the mutual recognition agreement (MRA) between the US and Europe that covers medical devices looks certain to slip.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.